Home Cart Sign in  
Chemical Structure| 1419949-20-4 Chemical Structure| 1419949-20-4

Structure of NVP-TNKS656
CAS No.: 1419949-20-4

Chemical Structure| 1419949-20-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, showing > 300 fold selectivity against PARP1 and PARP2.

Synonyms: TNKS656

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NVP-TNKS656

CAS No. :1419949-20-4
Formula : C27H34N4O5
M.W : 494.58
SMILES Code : O=C(N(CC1CC1)CC2=NC3=C(COCC3)C(N2)=O)CN4CCC(C(C5=CC=C(OC)C=C5)=O)CC4
Synonyms :
TNKS656
MDL No. :MFCD28167762
InChI Key :DYGBNAYFDZEYBA-UHFFFAOYSA-N
Pubchem ID :136237316

Safety of NVP-TNKS656

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of NVP-TNKS656

epigenetics
DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MHCC-97h 1.25 to 100 µM 3 days NVP-TNKS656 inhibited the proliferation of MHCC-97h cells in a dose-dependent manner. Cancer Cell Int. 2023 Nov 30;23(1):302.
SMMC-7721 1.25 to 100 µM 3 days NVP-TNKS656 inhibited the proliferation of SMMC-7721 cells in a dose-dependent manner. Cancer Cell Int. 2023 Nov 30;23(1):302.
MHCC-97h 1.25 to 100 µM 3 days NVP-TNKS656 inhibited the proliferation of MHCC-97h cells in a dose-dependent manner. J Cancer. 2020 Jan 1;11(2):432-440.
SMMC-7721 1.25 to 100 µM 3 days NVP-TNKS656 inhibited the proliferation of SMMC-7721 cells in a dose-dependent manner. J Cancer. 2020 Jan 1;11(2):432-440.
HCT116 isogenic cell lines (54, 240, 241) 5 µM 48 hours To evaluate the effect of NVP-TNKS656 combined with MEK inhibitor on colon cancer cells with different β-catenin genotypes. Results showed that β-catenin wild-type cells (241) responded to the combination treatment, while mutant (240) and mixed (54) cells did not. Br J Cancer. 2019 Apr;120(9):941-951.
HCT-8 5 µM 48 hours To evaluate the effect of NVP-TNKS656 combined with MEK inhibitor on PIK3CA mutant colon cancer cells. Results showed that the combination treatment significantly increased cell death. Br J Cancer. 2019 Apr;120(9):941-951.
DLD-1 5 µM 48 hours To evaluate the effect of NVP-TNKS656 combined with MEK inhibitor on PIK3CA mutant colon cancer cells. Results showed that the combination treatment significantly increased cell death. Br J Cancer. 2019 Apr;120(9):941-951.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice DLD-1 PIK3CA mt (cell line 353) xenograft model Intraperitoneal injection 50 mg/kg Once daily for 28 days To evaluate the effect of NVP-TNKS656 combined with MEK inhibitor on PIK3CA mutant colon cancer Mice model. Results showed that the combination treatment significantly suppressed tumor growth. Br J Cancer. 2019 Apr;120(9):941-951.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.02mL

0.40mL

0.20mL

10.11mL

2.02mL

1.01mL

20.22mL

4.04mL

2.02mL

References

 

Historical Records

Categories